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Chronic myeloid leukemia (CML) is caused by the BCR-ABL oncogene.  The Philadelphia chromosome 
(Ph) from a reciprocal translocation,  t(9;22) (q34;q11) causes a fusion gene,  BCR-ABL,  that encodes 
a constitutively active tyrosine kinase.  Treatment of CML by imatinib is eﬀective to control the tyrosyl 
phosphorylation of the protein related to the cell signaling.  BCR-ABL mRNA is overexpressed in the 
minimal residual disease (MRD),  known as an early sign of relapse.  Between December 2005 and June 
2008,  we measured BCR-ABL mRNA levels in the bone marrow (BM) from patients by quantitative 
real-time polymerase chain reaction (RQ-PCR) in Aomori Prefectural Central Hospital.  Eighty-six 
samples from 26 patients were collected.  Among the 26 CML patients,  11 patients (42ｵ) were in the 
pretreatment group.  Seven (64ｵ) of the 11 patients achieved complete molecular response (CMR).  In 
the post-treatment group consisting of the remaining 15 patients,  9 (60ｵ) patients achieved CMR.  The 
patients receiving imatinib at a dose over 300mg per day required 13 (6-77) months [median (range)] to 
achieve CMR.  On the other hand,  the patients receiving a dose below 300mg per day required 29.5 
(11-84) months [median (range)].  When BCR-ABL mRNA was detected during the treatment course of 
patients with CMR,  careful observation of BCR-ABL mRNA was useful for tracking the clinical 
course of patients.  In conclusion,  the BCR-ABL mRNA level was useful for monitoring the clinical 
course in 26 patients with CML.  
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hronic myeloid leukemia (CML) is a malignant 
hematological disorder caused by the BCR-ABL 
oncogene [1].  The Philadelphia chromosome (Ph) 
results from a reciprocal translocation between the 
long arms of chromosomes 9 and 22,  t(9;22)
(q34;q11) [2].  This translocation causes a fusion 
gene,  BCR-ABL,  which encodes a constitutively 
active tyrosine kinase [3].  Historically,  interferon α 
plus cytarabine was a mainstay as a standard therapy 
for patients with CML who couldnʼt undergo 
hematopoietic stem cell transplantation [4,  5].  
However,  imatinib mesylate (Gleevec®,  Novartis 
Pharmaceuticals,  East Hanover,  NJ,  USA),  a selec-
tive BCR-ABL tyrosine kinase inhibitor (TKI),  has 
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become the ﬁrst-line treatment for patients with CML 
[6-10].  Recently,  in addition to imatinib,  eﬀective 
second-line BCR-ABL inhibitors have begun to be used 
for patients who donʼt respond to imatinib because 
they are resistant or relapsed.  These drugs have 
increased speciﬁcity and potency as BCR-ABL inhibi-
tors compared with imatinib [11,  12].  
　 As long-term follow-up for CML therapy with 
BCR-ABL TKI,  minimal residual disease (MRD) 
monitoring is required.  MRD is known as an early 
sign of recurrence and represents the condition with 
low levels of leukemia cells in the bone marrow.  The 
level of BCR-ABL mRNA was reported to reﬂect the 
presence of MRD in patients with CML and to be a 
marker by which physicians can monitor disease status 
and treatment response,  even when the morphological 
ﬁndings indicate complete remission (CR) [13].  
　 We began measuring BCR-ABL mRNA in bone 
marrow (BM) samples using real-time quantitative 
polymerase chain reaction (PCR) methods in our hos-
pital in December 2005.  The purpose of the present 
study was to investigate retrospectively whether the 
BCR-ABL mRNA value could allow us to monitor 
patients with CML,  using a real-time quantitative 
PCR technique.  
Materials and Methods
　 Patients and materials. BM samples were 
collected from outpatients and inpatients diagnosed 
and treated in the Department of Hematology at 
Aomori Prefectural Central Hospital from December 
2005 to August 2008.  The BM samples were collected 
at diagnosis,  during therapy,  and during post-therapy 
follow-up.  Most samples were obtained as a part of 
diagnostic procedures.  Eighty-six samples from 26 
CML patients were collected.  
　 The 26 CML patients were divided into a pre-
treatment group of 11 patients and a post-treatment 
group of 15 patients (Table 1).  The pretreatment 
group received no remission induction therapy at 
diagnosis.  The post-treatment group had already 
received various types of treatment.  The 26 CML 
patients included 15 male and 10 female patients.  
Their median age was 56.5 years old (range,  27-77 
years).  Written informed consent for study participa-
tion was obtained from all of the patients.  The proto-
col was approved by the ethical committee of Aomori 
Prefectural Central Hospital.  
　 Clinical criteria and treatment strategy.
For this study,  the chronic phase (CP) of CML was 
deﬁned by the presence of less than 15 percent blasts,  
less than 20 percent basophils,  and less than 30 per-
cent blasts plus promyelocytes in the peripheral blood 
and marrow.  
　 A complete hematologic response (CHR) was 
deﬁned as a white blood cell (WBC) count of ＜10×
109/L,  a platelet count of ＜450×109/L,  no imma-
ture cells (blasts,  promyelocytes,  myelocytes) in the 
peripheral blood,  and disappearance of all signs and 
symptoms related to leukemia.  A cytogenetic response 
was categorized as complete (0ｵ Ph-positive),  partial 
(1-34ｵ Ph-positive),  or minor (35-90ｵ Ph-positive).  
A major cytogenetic response included complete plus 
partial cytogenetic responses (Ph-positive ＜35ｵ).  
Cytogenetic response was judged by standard cytoge-
netic analysis.  We propose that a reduction in BCR-
ABL mRNA levels of at least 3 log be used to deﬁne a 
major molecular response.  A complete molecular 
response was deﬁned as undetectable levels of BCR-
ABL mRNA [13,  14].
　 Patients orally received imatinib 100-400mg/day.  
The imatinib dose was adjusted according to response 
and tolerance.  The change of treatment strategy and 
the result based on the level of BCR-ABL mRNA were 
observed.  Drug toxicity was evaluated using the 
National Cancer Institute Common Toxicity Criteria 
(version 2.0).  
　 RNA extraction and cDNA synthesis. The 
BM from the patients was processed with RBC Lysis 
Buﬀer (Roche Diagnostics,  Basel,  Switzerland).  
Total RNA was extracted using the High Pure RNA 
Isolation Kit (Roche),  following the manufacturerʼs 
instructions.  BM was stirred at 25℃ for 10min,  and 
total RNA was extracted.  Quality of the extracted 
RNA was checked by a spectrophotometer/ optical 
density instrument,  the Gene Quant pro (GE 
Healthcare Bio-Sciences,  Tokyo,  Japan).  We per-
formed 1ｵ agarose gel electrophoresis of the RNA,  
For complementary DNA (cDNA) synthesis,  reverse 
transcription (RT) was performed with the 
Transcripter First Strand cDNA Synthesis Kit 
(Roche) according to the manufacturerʼs instruction.  
The synthesized cDNA was stored at －80℃ until 
use.  
　 Real-time quantitative PCR of BCR-ABL 
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mRNA. Real-time quantitative polymerase chain 
reaction (RQ-PCR) reactions and ﬂuorescence mea-
surements were performed on the LightCycler 2.0 
instrument (Roche).  A LightCycler primer and probe 
set (Roche) was used for quantitative assessment.  
Primers for Human Major bcr/abl (Roche,  GenBank 
Accession: AJ131466) and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH: Roche,  GenBank 
Accession: M33197),  and LightCyler-FastStart DNA 
Master Hybridization Probe (Roche) were used.  PCR 
was performed on the LightCycler 2.0 instrument 
(Roche) according to the manufacturerʼs instruction.  
The resulting data were treated with LightCycler 
Software (Roche).  
　 The normal range of BCR-ABL mRNA expression 
levels was determined in peripheral blood from 34 
healthy volunteers with their informed consent and 
normalized to the GAPDH levels as an internal con-
trol.  When BCR-ABL mRNA expression levels were 
detected,  the samples were judged as positive.  All 34 
samples from healthy volunteers were negative.  
　 Statistical analysis. All of these analyses were 
carried out using Microsoft Excel software 
(Microsoft Corp.,  Redmond,  WA,  USA) and JMP®8 
software (SAS Institute,  Cary,  NC,  USA).  A two-
tailed unpaired t-test analysis was performed to com-
pare the duration of treatment.  
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Table 1　 All CML patients and samples
No. Pre or post treatment Age Sex Phase 
First BCR-ABL mRNA 
(copies/µg RNA) Therapy Response
Adverse events of 
imatinib
CTC 
grade
 1 Pre 65 F CP 21,000 Dasatinib+PSL CHR
 2 Pre 50 F CP 21,000 Imatinib 400mg CMR (6) T 3
 3 Pre 27 M CP 10,000 Imatinib 400mg CMR (9) M 1
 4 Pre 42 M CP 9,600 Imatinib 300mg CMR (8) S 2
 5 Pre 60 M CP 11,000 Imatinib 100mg CHR
 6 Pre 27 F CP 15,000 Imatinib 200mg CMR (15) M, S 2, 2
 7 Pre 51 M CP » AP 8,800 Imatinib » BMT CMR (7) N 3
 8 Pre 73 F CP 8,800 Imatinib 200mg CCR N, T 2, 2
 9 Pre 74 M CP 28,000 Imatinib 400mg -
10 Pre 51 M CP 17,000 Imatinib 400mg CMR (9) T 2
11 Pre 35 F CP 9,200 Ara-C » imatinib 300mg MMR N, T 2, 2
12 Post 66 F CP 0 Imatinib 400mg CMR (13) 
13 Post 54 F CP 0 Imatinib 400 » 300mg CMR (77) E 2
14 Post 66 M CP 0 Imatinib 400 » 200mg CMR (44) S 2
15 Post 73 F CP 0 Imatinib 100mg CMR (84) S 2
16 Post 75 F CP 0 Imatinib 400mg CMR (48) 
17 Post 46 M CP 0 Imatinib 400mg CMR (42) 
18 Post 82 F CP » BC 19,000 HU+ IFN » Imatinib 400mg CHR
19 Post 59 M CP 0 Imatinib 300mg CCR E 2
20 Post 72 M CP 4,000 Imatinib 300mg CCR C 1
21 Post 44 M CP 0 Imatinib 400mg CCR
22 Post 77 M CP 0 Imatinib 300mg CMR (31) 
23 Post 41 M AP 0 Imatinib 300mg MMR N 3
24 Post 44 M CP 0 Imatinib 400 » 200mg CMR (11) S 2
25 Post 42 M CP 0 Imatinib 400 » 300mg CMR (25) M 2
26 Post 61 M CP 6,500 Imatinib 400 » 300mg MCR S 2
Samples were collected in the Department of Hematology at Aomori Prefectural Central Hospital between October 2005 and July 2008.  
Twenty-six CML patients were divided into 15 post-treatment patients and 11 pretreatment patients.  (  ) indicated months to achieve CMR.  
AP,  accelerated phase; Ara-C,  cytarabine; BC,  blastic crisis; BMT,  bone marrow transplantation; C,  elevated creatinine; CCR,  com-
plete cytogenetic response; CHR,  complete hematological response; CMR,  complete molecular response; CP,  chronic phase; E,  
edema; HU,  hydroxyurea; IFN,  interferon; M,  myalgia; MCR,  major cytogenic response; MMR,  major molecular response; N,  
neutropenia; T,  thrombocytopenia; S,  skin lesion; -,  no follow up.  
Results
　 At diagnosis,  all patients in the pretreatment 
group showed an overexpression of BCR-ABL mRNA 
(11/11,  100ｵ).  The median value was 11,000 cop-
ies/㎍ RNA,  with a range of 8,800 to 21,000 (Table 
1).  Two (18ｵ),  1 (9ｵ),  1 (9ｵ),  and 6 (55ｵ) of 
them achieved CHR,  complete cytogenic response 
(CCR),  major molecular response (MMR),  and CMR,  
respectively,  after the start of imatinib therapy (Fig.  
1).  One patient (No.  9) could not continue imatinib 
treatment.  In the post-treatment group,  1 (6.66ｵ),  
1 (6.66ｵ),  3 (20ｵ),  1 (6.66ｵ),  and 9 (60ｵ) of the 
15 patients achieved CHR,  MCR,  CCR,  MMR,  and 
CMR,  respectively.  
　 In the post-treatment group,  there were 3 patients 
(nos.  18,  20,  and 26) in whom values of the BCR-
ABL mRNA were above the cutoﬀ.  Patient no.  18 
was treated with hydroxyurea and interferon (HU＋
IFN).  BCR-ABL mRNA was high after blastic crisis 
in this patient,  in spite of the treatment with imatinib 
for 5 years.  In patient no.  20,  the ﬁrst measurement 
of BCR-ABL mRNA levels was high.  CCR but not 
CMR was achieved due to resistance against imatinib 
treatment.  Additional measurement of this patient will 
occur in the future.  Patient no.  26 achieved MCR at 
9 months after the completion of treatment because of 
bad compliance with imatinib treatment.  Patient no.  
23 achieved MMR and continued imatinib therapy at a 
dose of 300mg.  BCR-ABL mRNA was elevated to 
91copies/ml in this patient.  Also,  in patient no.  13,  
BCR-ABL mRNA rose to 100copies/ml in the clinical 
course.  With careful observation during imatinib 
treatment,  BCR-ABL mRNA became negative again in 
these patients.  Maintaining the previous treatment 
resulted in continued CMR in most patients of the 
post-treatment group.  
　 The patients receiving imatinib at a dose over 
300mg per day (nos.  2,  3,  4,  7,  9,  10,  11,  12,  13,  
16,  17,  18,  19,  20,  21,  22,  23,  25,  and 26) were 
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Fig. 1　 BCR-ABL mRNA levels of 11 pretreatment patients.
Patient no.  2 was treated with 400mg/day of imatinib,  and CMR was continuously achieved.  Patient no.  7 received BMT after imatinib 
therapy.  After CMR,  the patient was treated with BMT and followed with immunosuppressive agents.  BCR-ABL mRNA levels remained 
negative.  m: months.  
compared with the patients receiving imatinib at a dose 
below 300mg per day (nos.  5,  6,  8,  14,  15,  and 
24).  The ratio of CHR,  MCR,  CCR,  MMR,  and 
CMR among the patients receiving over 300mg of 
imatinib per day was 5.3ｵ (1/19),  5.3ｵ (1/19),  
15.8ｵ (3/19),  10.5ｵ (2/19),  and 57.9ｵ (11/19),  
respectively.  One patient (No.  9) could not continue 
imatinib treatment.  In the patients below that treat-
ment level,  the ratio of CHR,  CCR,  and CMR was 
16.7ｵ (1/6),  16.7ｵ (1/6),  and 66.6ｵ (4/6),  respec-
tively.  The patients receiving imatinib at a dose over 
300mg per day required 13 (6-77) months [median 
(range)] to achieve CMR.  On the other hand,  the 
patients receiving imatinib at a dose below 300mg per 
day required 29.5 (11-84) months [median (range)] to 
achieve CMR.  The eﬀectiveness of imatinib therapy 
was dose-volume dependent.  Unfortunately,  there was 
no signiﬁcant diﬀerence between the 2 groups (p＝
0.384).  
　 Adverse eﬀects of imatinib therapy in the 26 CML 
patients are shown in Table 2.  For over half of the 
patients (17/26),  the dose of 400mg/day of imatinib 
was discontinued because of adverse events.  
Hematological toxicity was seen in 6 patients 
(26.1ｵ; nos.  2,  7,  8,  10,  11,  and 23).  Non-
hematological toxicity was seen in 11 patients 
(42.3ｵ; nos.  3,  4,  6,  13,  14,  15,  19,  20,  24,  25,  
and 26).  In the post-treatment group,  some patients 
required imatinib dose reduction.  When BCR-ABL 
mRNA was detected in the treatment course of the 
patients with CMR,  careful observation of BCR-ABL 
mRNA was useful to survey the clinical course of 
CML patients (Fig.  2).  
　 Patient no.  1 with CML was treated with dasat-
inib.  This patient was resistant to imatinib as a ﬁrst 
regimen with the dosage of 400mg/day.  This change 
to dasatinib allowed the patient to achieve CHR but 
not CCR.  BCR-ABL mRNA was not analyzed again 
because of the presence of blast cells in the BM 
analysis for this patient.  
Discussion
　 The eﬃcacy of imatinib has been reported in newly 
diagnosed CML patients [16,  17].  Frequent monitor-
ing of BCR-ABL mRNA is required among the ima-
tinib treatment patients,  except in patients remaining 
susceptible to imatinib for 2-3 years.  However,  
annual rates of treatment failure during the 
International Randomized Study of Interferon and 
STI571 (IRIS) were 3.3-7.5ｵ during the ﬁrst 3 
years [18].  Thirty to ﬁfty percent of CML patients 
require substitute or additional treatment,  and the 
disease statuses of these patients need to be fre-
quently monitored.  Frequent monitoring by molecular 
methods every 2 to 3 months in patients with CCR 
were reported [19].  In our study,  when bone marrow 
was analyzed,  the level of BCR-ABL mRNA in BM 
was simultaneously monitored at an interval of 1-3 
months.
　 BCR-ABL-dependent factors associated with ima-
tinib resistance included a lot of ampliﬁcation of BCR-
ABL and the mutation of BCR-ABL kinase domain 
[20-22].  The point mutations can change the struc-
ture of BCR-ABL kinase protein,  which makes ima-
tinib unable to bind to BCR-ABL kinase.  The T315I 
mutation gives rise to a highly resistant kinase present 
in 50-90ｵ of relapsed CML patients [23-26].  The 
screening for BCR-ABL mutations is not necessarily 
required in patients that respond to imatinib.  
However,  when the eﬀectiveness of imatinib is 
reduced,  or the BCR-ABL mRNA is overexpressed at 
least 2-fold of the MMR,  the mutation should be 
checked [27-29].  In our study,  imatinib was not 
eﬀective in patient no.  1,  who was later treated with 
dasatinib.  The mutation should be checked in this 
patient,  but could not yet be done within the time-
frame of this study.  
　 BCR-ABL non-dependent factors of imatinib resis-
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Table 2　 Adverse events of imatinib in 26 CML patients
Events Cases CTC grade
Hematological toxicity
　Thrombocytopenia 4 2, 2, 2, 3
　Neutropenia 4 2, 2, 3, 3
Non-hematological toxicity
　Elevated serum creatinine level 1 1
　Myalgia 3 1, 2, 2
　Rash 6 2, 2, 2, 2, 2, 2
　Superficial edema 2 2, 2
All 20 (17 patients)
The dose of 400mg/day of imatinib was not continued due to 
adverse events in 14 cases.  Hematological toxicity was seen in 8 
cases (6 patients,  23.1％).  Non-hematological toxicity was seen in 
12 cases (11 patients,  42.3％).
tance have been reported,  for example,  when p-glyco-
protein encoded by the MDR-1 gene excretes imatinib 
and plasma binding of α-1 acid glycoprotein with ima-
tinib prevents the drug from reaching its target pro-
tein [30,  31].  Dasatinib (Sprycel®,  Bristol-Myers 
Squibb,  Princeton,  NJ,  USA) has both BCR-ABL 
and SRC inhibitory activity.  In patient no.  1,  who 
was resistant to imatinib therapy,  dasatinib therapy 
was started and the patient achieved CHR.  
　 Overexpression of BCR-ABL mRNA is predictive 
of a subsequent loss of response,  and increased doses 
of imatinib may be required [20,  27,  32,  33].  In 
patients with CCR,  it is important to achieve CMR by 
quantifying BCR-ABL mRNA levels continuously.  
RQ-PCR analysis to quantify the amount of CML 
residual disease,  particularly in patients with CCR,  
showed a 3-log reduction of disease in approximately 
40ｵ to 60ｵ of patients [8,  14,  16,  21].  Some 
studies have associated a two-fold,  a 0.5-log,  or a 
1-log increase of molecular disease with a higher rate 
of detection of mutations and/or a higher relapse rate.  
In the present study,  7 patients (nos.  2,  3,  4,  6,  7,  
10,  and 11) achieved marked reduction of BCR-ABL 
mRNA levels with imatinib treatment.  When BCR-
ABL mRNA exceeds the cutoﬀ level during the clini-
cal course,  disease status should be observed more 
carefully and the treatment strategy might need to be 
changed.  
　 Frequent monitoring using a sensitive RQ-PCR 
method is important.  However,  diﬀerent sources of 
samples,  diﬀerent handling procedures of samples,  
and a mixture of data from diﬀerent laboratories can 
confuse the medical staﬀ about the results.  In our 
study,  the bone marrow was used as a sample to 
evaluate the patient at the same time as we evaluated 
BCR-ABL mRNA.  In preliminary experiments,  there 
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Fig. 2　 BCR-ABL mRNA levels of 15 post-treatment patients.
In patients no.  23 and no.  13 with CMR,  BCR-ABL mRNA was detected intermittently.  Patient no.  23 achieved CMR and continued 
imatinib at a dose of 300mg/day.  BCR-ABL mRNA was elevated to 91copies/ml.  Also,  in patient no.  13,  BCR-ABL mRNA was elevated 
to 100copies/ml during the clinical course.  With careful observation during imatinib treatment,  BCR-ABL mRNA became negative again in 
these patients.  In patient no.  18,  BCR-ABL mRNA was high after blastic crisis.  Patient no.  20 could achieve CCR but not CMR due to 
resistance against imatinib.  Patient no.  26 achieved MCR at 9 months after the imatinib treatment because of bad compliance with 
treatment.  m: months.
was no diﬀerence in BCR-ABL mRNA levels between 
the marrow and the peripheral blood (data not shown).  
Our hospital established a technique of BCR-ABL 
mRNA quantiﬁcation,  and this method is more useful 
than past methods for assessing the absolute quantity 
of BCR-ABL.  Standardization is needed to improve 
the commercial kits in the future,  including the selec-
tion of the housekeeping gene used as an internal 
control.  
　 Severe adverse events make some patients reduce 
the dose of imatinib or stop treatment temporarily,  
despite the relatively good tolerability of imatinib.  
Imatinib therapy at a dose over 300mg/day has better 
eﬀectiveness than therapy at a dose below 300mg/
day [10].  Reducing the dose to 200mg/day after 
achieving CMR has been found to be eﬀective in ima-
tinib-intolerant patients.  However,  it remains unclear 
whether low-dose imatinib or treatment interruption 
after CMR is eﬀective compared to the standard dose 
in maintaining CMR [15,  21,  31,  34,  35].  Three 
patients in our study (nos.  6,  14,  and 24) were 
treated with 200mg/day imatinib.  They achieved and 
maintained CMR.  In this context,  continuous monitor-
ing of BCR-ABL mRNA levels is required.  
　 In the present study,  we investigated the clinical 
utility of BCR-ABL mRNA in 26 CML patients.  
Using our RQ-PCR methods,  careful observation of 
BCR-ABL mRNA was useful to survey the clinical 
course of CML patients.  
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